These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 23795241)
1. Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase. Zheng B; Yao Y; Liu Z; Deng L; Anglin JL; Jiang H; Prasad BV; Song Y ACS Med Chem Lett; 2013 Jun; 4(6):542-546. PubMed ID: 23795241 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of cancer-associated mutant isocitrate dehydrogenases: synthesis, structure-activity relationship, and selective antitumor activity. Liu Z; Yao Y; Kogiso M; Zheng B; Deng L; Qiu JJ; Dong S; Lv H; Gallo JM; Li XN; Song Y J Med Chem; 2014 Oct; 57(20):8307-18. PubMed ID: 25271760 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer. Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149 [TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. Deng G; Shen J; Yin M; McManus J; Mathieu M; Gee P; He T; Shi C; Bedel O; McLean LR; Le-Strat F; Zhang Y; Marquette JP; Gao Q; Zhang B; Rak A; Hoffmann D; Rooney E; Vassort A; Englaro W; Li Y; Patel V; Adrian F; Gross S; Wiederschain D; Cheng H; Licht S J Biol Chem; 2015 Jan; 290(2):762-74. PubMed ID: 25391653 [TBL] [Abstract][Full Text] [Related]
5. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. Wu F; Jiang H; Zheng B; Kogiso M; Yao Y; Zhou C; Li XN; Song Y J Med Chem; 2015 Sep; 58(17):6899-6908. PubMed ID: 26280302 [TBL] [Abstract][Full Text] [Related]
7. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants. Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606 [TBL] [Abstract][Full Text] [Related]
8. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs. Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884 [TBL] [Abstract][Full Text] [Related]
10. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer. Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596 [TBL] [Abstract][Full Text] [Related]
11. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1 Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607 [TBL] [Abstract][Full Text] [Related]
12. A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas. Casar-Borota O; Øystese KA; Sundström M; Melchior L; Popovic V Pituitary; 2016 Aug; 19(4):407-14. PubMed ID: 27097804 [TBL] [Abstract][Full Text] [Related]
13. Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors. Liu S; Abboud M; Mikhailov V; Liu X; Reinbold R; Schofield CJ J Med Chem; 2023 Apr; 66(7):5279-5288. PubMed ID: 36952395 [TBL] [Abstract][Full Text] [Related]
14. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1). Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781 [TBL] [Abstract][Full Text] [Related]
15. Discovery of novel Hu C; Zeng Z; Ma D; Yin Z; Zhao S; Chen T; Tang L; Zuo S Front Pharmacol; 2022; 13():982375. PubMed ID: 36160383 [TBL] [Abstract][Full Text] [Related]
16. Identification of a new selective chemical inhibitor of mutant isocitrate dehydrogenase-1. Kim HJ; Choi BY; Keum YS J Cancer Prev; 2015 Mar; 20(1):78-83. PubMed ID: 25853107 [TBL] [Abstract][Full Text] [Related]
17. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas. Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors. Chitneni SK; Reitman ZJ; Spicehandler R; Gooden DM; Yan H; Zalutsky MR Bioorg Med Chem Lett; 2018 Feb; 28(4):694-699. PubMed ID: 29366652 [TBL] [Abstract][Full Text] [Related]
19. RNA-Binding Protein HuR Regulates Both Mutant and Wild-Type IDH1 in IDH1-Mutated Cancer. Zarei M; Lal S; Vaziri-Gohar A; O'Hayer K; Gunda V; Singh PK; Brody JR; Winter JM Mol Cancer Res; 2019 Feb; 17(2):508-520. PubMed ID: 30266754 [TBL] [Abstract][Full Text] [Related]